omeprazole + domperidone + ranitidine

This combination therapy consists of the proton pump inhibitor (PPI) omeprazole, the dopamine D2 receptor antagonist domperidone, and the H2-receptor antagonist (H2RA) ranitidine. It is primarily utilized as an intensified anti-reflux regimen for patients suffering from refractory gastroesophageal reflux-induced cough (GERC), particularly those who have failed standard PPI monotherapy. The therapeutic rationale involves achieving profound and sustained suppression of gastric acid through two distinct pathways—irreversible inhibition of the H+/K+-ATPase pump by omeprazole and competitive inhibition of histamine H2 receptors by ranitidine—while domperidone acts as a prokinetic to enhance gastric emptying and increase lower esophageal sphincter pressure. This multi-targeted approach aims to minimize both acidic and non-acidic refluxate that triggers the cough reflex. Clinical research into this specific triple combination has been notably conducted by investigators at Shanghai Tongji Hospital.

Other names

PPI + prokinetic + H2RA triple therapyintensified anti-reflux therapy